|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 335.17 USD | -0.15% |
|
-1.30% | -0.37% |
| 06/01 | Drug Distributors Poised for Growth Amid Emerging Risks, BofA Says | MT |
| 23/12 | Cencora Insider Sold Shares Worth $1,750,221, According to a Recent SEC Filing | MT |
| Capitalization | 65.12B 55.99B 52.2B 48.58B 90.49B 5,876B 97.51B 600B 236B 2,809B 244B 239B 10,294B | P/E ratio 2026 * |
24.1x | P/E ratio 2027 * | 20.6x |
|---|---|---|---|---|---|
| Enterprise value | 66.31B 57.01B 53.15B 49.46B 92.14B 5,983B 99.29B 611B 240B 2,861B 249B 244B 10,482B | EV / Sales 2026 * |
0.19x | EV / Sales 2027 * | 0.18x |
| Free-Float |
35.16% | Yield 2026 * |
0.68% | Yield 2027 * | 0.71% |
Last Transcript: Cencora, Inc.
| 1 day | -0.16% | ||
| 1 week | -1.30% | ||
| Current month | -0.37% | ||
| 1 month | -2.75% | ||
| 3 months | +6.15% | ||
| 6 months | +13.27% | ||
| Current year | -0.37% |
| 1 week | 333.79 |  | 349.55 |
| 1 month | 329.1 | | 351.99 |
| Current year | 329.1 | | 349.55 |
| 1 year | 233.61 | | 377.54 |
| 3 years | 147.48 | | 377.54 |
| 5 years | 100.71 | | 377.54 |
| 10 years | 68.38 | | 377.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Mauch
CEO | Chief Executive Officer | 59 | 01/10/2024 |
James Cleary
DFI | Director of Finance/CFO | 63 | 09/11/2018 |
Pawan Verma
CTO | Chief Tech/Sci/R&D Officer | 50 | 04/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Lon Greenberg
BRD | Director/Board Member | 75 | 16/05/2013 |
Robert Mauch
BRD | Director/Board Member | 59 | 01/10/2024 |
D. Mark Durcan
CHM | Chairman | 64 | 01/10/2025 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.15% | -1.30% | +42.53% | +104.06% | 65.12B | |
| -1.70% | -1.96% | +9.52% | +11.32% | 219B | |
| -1.28% | -1.03% | +17.81% | +20.68% | 125B | |
| -0.18% | +1.99% | -14.09% | -20.30% | 57.77B | |
| -0.24% | +5.51% | +22.53% | +87.40% | 53.45B | |
| +4.17% | +7.97% | - | - | 33.72B | |
| +5.71% | +4.44% | -11.50% | -34.05% | 26.29B | |
| +0.02% | +0.07% | +23.89% | +28.31% | 25.21B | |
| +0.14% | +0.09% | +5.30% | -32.30% | 24.25B | |
| -0.66% | -0.15% | -24.25% | +24.16% | 21.15B | |
| Average | +0.60% | +1.80% | +7.97% | +21.03% | 65.09B | |
| Weighted average by Cap. | -0.41% | +1.73% | +11.97% | +24.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 341B 293B 273B 254B 473B 30,731B 510B 3,138B 1,233B 14,693B 1,277B 1,251B 53,840B | 363B 312B 291B 271B 504B 32,730B 543B 3,342B 1,314B 15,648B 1,360B 1,332B 57,342B |
| Net income | 2.39B 2.05B 1.91B 1.78B 3.32B 216B 3.58B 22.01B 8.65B 103B 8.96B 8.78B 378B | 3.12B 2.69B 2.5B 2.33B 4.34B 282B 4.68B 28.79B 11.32B 135B 11.72B 11.48B 494B |
| Net Debt | 1.19B 1.02B 953M 886M 1.65B 107B 1.78B 10.95B 4.3B 51.26B 4.46B 4.36B 188B | -1.1B -946M -882M -820M -1.53B -99.24B -1.65B -10.13B -3.98B -47.45B -4.12B -4.04B -174B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 336.54 $ | +0.25% | 155,580 |
| 09/01/26 | 335.69 $ | -0.01% | 916,997 |
| 08/01/26 | 335.74 $ | -1.37% | 1,133,960 |
| 07/01/26 | 340.41 $ | -1.66% | 988,680 |
| 06/01/26 | 346.17 $ | +1.54% | 1,413,415 |
Delayed Quote Nyse, 13 January 2026 at 03:17 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- COR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition